New Delhi: Drug major Lupin on Tuesday said it has launched Amabelz tablets, used in prevention of postmenopausal osteoporosis, in the American market after getting approval from the US US health regulator - the US Food and Drug Administration (FDA).
Lupin Pharmaceuticals Inc, a subsidiary of the company, has launched Amabelz tablets, a generic version of Amneal Pharmaceuticals' Activella tablets, in the US, Lupin said in a statement.
According to IMS MAT sales data, Activella had US sales of $91.1 million.
Shares in Lupin ended 1.37 per cent lower at Rs 1,440.20 apiece on the BSE, whose benchmark Sensex index finished down 1.92 per cent.
New Delhi: Drug major Lupin on Tuesday said it has launched Amabelz tablets, used in prevention of postmenopausal osteoporosis, in the American market after getting approval from the US US health regulator - the US Food and Drug Administration (FDA).
Lupin Pharmaceuticals Inc, a subsidiary of the company, has launched Amabelz tablets, a generic version of Amneal Pharmaceuticals' Activella tablets, in the US, Lupin said in a statement.
According to IMS MAT sales data, Activella had US sales of $91.1 million.
Shares in Lupin ended 1.37 per cent lower at Rs 1,440.20 apiece on the BSE, whose benchmark Sensex index finished down 1.92 per cent.
New Delhi: Drug major Lupin on Tuesday said it has launched Amabelz tablets, used in prevention of postmenopausal osteoporosis, in the American market after getting approval from the US US health regulator - the US Food and Drug Administration (FDA).
Lupin Pharmaceuticals Inc, a subsidiary of the company, has launched Amabelz tablets, a generic version of Amneal Pharmaceuticals' Activella tablets, in the US, Lupin said in a statement.
According to IMS MAT sales data, Activella had US sales of $91.1 million.
Shares in Lupin ended 1.37 per cent lower at Rs 1,440.20 apiece on the BSE, whose benchmark Sensex index finished down 1.92 per cent.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)